
Keywords: کورتیکواستروئید موضعی; fixed combination; halobetasol; psoriasis; tazarotene; topical; AE; adverse event; BSA; body surface area; DLQI; Dermatology Life Quality Index; HP/TAZ; halobetasol propionate 0.01% plus tazarotene 0.045%; IGA; Investigator's Global Assessment; QoL; quali